PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results

Key Points

• Heterogeneity to chemotherapy response is observed in PD-L1 subpopulations.
• Outcomes across diverse PD-L1 levels indicate differing treatment effectiveness.
• Integrated analysis of digitized trial results supports refined therapeutic strategies.
• Implications suggest personalized treatment regimens could improve patient outcomes.